Amgen Stock Hits New High After Strong Q2 Results and Raised Guidance

Amgen stock is trading near its 52-week high at $439.33 after delivering strong second-quarter results and raising full-year earnings guidance in August 2026.

The biotechnology group posted EPS of $6.29, beating the consensus estimate by almost 12% and improving from $6.02 in the same quarter a year earlier. Revenue reached $10.05 billion, representing 9.5% year-over-year growth and a beat of $0.62 billion against analyst expectations.

Management issued fiscal 2026 earnings guidance in a range of $22.30 to $23.50 per share, with the midpoint implying solid full-year growth compared with current-year analyst expectations.

The company's stable dividend payout policy and generous cash distribution contribute to its defensive growth profile, supported by strong free cash flow and disciplined capital allocation.